Starting in the 1980s, interferon (IFN)-α was the primary treatment for Chronic Myeloid Leukemia (CML), offering a reduction in disease burden and a modest improvement in survival compared to other treatments. Here, IFNA17 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.